[1] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

[2] [Discontinuation of immunosuppressive and immunomodulatory drugs in connective tissue diseases]

[3] Certolizumab pegol for induction of remission in Crohn's disease

[4] What happens after complete withdrawal of therapy in patients with lupus nephritis

[5] Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society

[6] Remission and withdrawal of therapy in lupus nephritis

[7] Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

[8] Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

[9] [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission]

[10] Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial

[11] Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991

[12] Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

[13] Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group

[14] Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial

[15] Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life

[16] A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)

[17] Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease

[18] Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice

[19] Adalimumab induces deep remission in patients with Crohn's disease

[20] Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease

[21] Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

[22] Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

[23] Epidemiology of influenza A virus infection in patients with acute or chronic leukemia

[24] Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

[25] Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

[26] Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

[27] Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991